457 related articles for article (PubMed ID: 29964036)
1. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
2. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.
Liou JM; Chen CC; Chang CY; Chen MJ; Fang YJ; Lee JY; Chen CC; Hsu SJ; Hsu YC; Tseng CH; Tseng PH; Chang L; Chang WH; Wang HP; Shun CT; Wu JY; Lee YC; Lin JT; Wu MS;
J Antimicrob Chemother; 2013 Feb; 68(2):450-6. PubMed ID: 23099849
[TBL] [Abstract][Full Text] [Related]
4. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Kim JL; Cho SJ; Chung SJ; Lee A; Choi J; Chung H; Kim SG
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00194. PubMed ID: 33094958
[TBL] [Abstract][Full Text] [Related]
5. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
[TBL] [Abstract][Full Text] [Related]
8. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
[TBL] [Abstract][Full Text] [Related]
12. Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ; Chen PY; Fang YJ; Bair MJ; Chen CC; Chen CC; Yang TH; Lee JY; Yu CC; Kuo CC; Chiu MC; Chou CK; Chen CY; Hu WH; Tsai MH; Hsu YC; Shun CT; Luo JC; Lin JT; El-Omar EM; Wu MS; Liou JM;
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):623-634. PubMed ID: 37178702
[TBL] [Abstract][Full Text] [Related]
13. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Chen KY; Lin TJ; Lin CL; Lee HC; Wang CK; Wu DC
World J Gastroenterol; 2015 Sep; 21(36):10435-42. PubMed ID: 26420970
[TBL] [Abstract][Full Text] [Related]
14. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Liou JM; Chen CC; Chang CY; Chen MJ; Chen CC; Fang YJ; Lee JY; Yang TH; Luo JC; Wu JY; Liou TC; Chang WH; Hsu YC; Tseng CH; Chang CC; Bair MJ; Liu TY; Hsieh CF; Tsao FY; Shun CT; Lin JT; Lee YC; Wu MS;
Gut; 2016 Nov; 65(11):1784-1792. PubMed ID: 26338825
[TBL] [Abstract][Full Text] [Related]
16. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
17. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.
Paoluzi OA; Del Vecchio Blanco G; Visconti E; Coppola M; Fontana C; Favaro M; Pallone F
World J Gastroenterol; 2015 Jun; 21(21):6698-705. PubMed ID: 26074708
[TBL] [Abstract][Full Text] [Related]
18. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
[TBL] [Abstract][Full Text] [Related]
19. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
[TBL] [Abstract][Full Text] [Related]
20. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
